Effects of Functional Oils on Obesity With Mild Cognitive Impairment

NCT07690384 · tracked via the Priya Life Science China tracker

Sponsor

Capital Medical University

Phase

Not applicable

Started

2026-07

Last updated

2026-07-08

Condition(s) studied

ObesityMild Cognitive Impairment

Investigational drug(s) / intervention(s)

Rapeseed Oil (RSO)Diacylglycerol Oil (DAG Oil)

Rapeseed Oil (RSO): A commercially available conventional rapeseed oil for daily household cooking use, containing diacylglycerol (DAG) only at the trace level naturally occurring in regular vegetable oil.

Diacylglycerol Oil (DAG Oil): A rapeseed oil-based functional oil produced via lipase-catalyzed enzymatic conversion, with a diacylglycerol content ≥40% (national standard requirement), for daily household cooking use in place of conventional cooking oil.

Study summary

The purpose of this study is to investigate the effects of diacylglycerol (DAG) oil on obesity accompanied by mild cognitive impairment (MCI). Participants aged 45 to 75 years with obesity and MCI will be randomly assigned to two groups: a control group receiving regular rapeseed oil (RSO) and an experimental group receiving rapeseed-based DAG oil. The dietary intervention will last for 6 months. The main goal is to observe whether this functional oil intervention can improve cognitive function and regulate white adipose tissue browning.

Eligibility

Sex

ALL

Min age

45 Years

Max age

75 Years

Healthy volunteers

Inclusion Criteria: * Meets the diagnostic criteria for obesity combined with mild cognitive impairment (MCI) (obesity: BMI ≥28.0 kg/m\^2 per the 2022 Chinese Expert Consensus on Obesity Prevention and Treatment; MCI: Montreal Cognitive Assessment \[MoCA\] score below the education-adjusted cutoff, confirmed by a neurologist) * Aged 45 to 75 years * Has not been on a diet or has discontinued dieting for at least 3 months, and has not taken fish oil or similar supplements, or is willing to discontinue such supplements for 3 months prior to the intervention * Able to accept and consume DAG oil as part of daily diet * Voluntarily agrees to participate and signs the informed consent form Exclusion Criteria: * History of neuropsychiatric disorders such as stroke, epilepsy, or schizophrenia * Cognitive impairment attributable to depression, thyroid disease, traumatic brain injury, or drug- or alcohol-induced intoxication * History of cerebrovascular disease, or cognitive decline due to severe impairment of cardiac, hepatic, pulmonary, or renal function * Use of antibiotics, health products, or nutritional supplements within 2 weeks prior to fecal sample collection; or gastrointestinal symptoms (trauma, inflammation/infection, abdominal pain, diarrhea, or constipation) or vaccination history within the same period

Primary outcome measure(s)

Change From Baseline in Cognitive Function — Baseline and 6 months
Change from baseline in cognitive function assessed by the Montreal Cognitive Assessment (MoCA), which evaluates visuospatial/executive function, naming, memory, attention, language, abstraction, delayed recall, and orientation. Total score ranges from 0 to 30, with higher scores indicating better cognitive function.
Change From Baseline in Body Weight — Baseline and 6 months
Change from baseline in body weight (kg) measured by bioelectrical impedance analysis (InBody body composition analyzer).
Change From Baseline in Body Fat Percentage — Baseline and 6 months
Change from baseline in body fat percentage measured by bioelectrical impedance analysis (InBody body composition analyzer).

Trial sites (1)

Facility	City	Region	Status
Capital Medical University	Beijing	Beijing Municipality

More Capital Medical University trials in China

Pregnancy Anti-inflammatory Diet Intervention Study Starting soon

Cerebral Venous Thrombosis Cohort Study in China Mainland Recruiting

Safety and Efficacy of Carotid Artery Stenting Combined With Intermittent Hypoxia Intervention in Patients With Severe Internal Carotid Artery Stenosis Starting soon

Telemedicine-supported Management for Acute Ischemic Stroke Recruiting

Effect of Target Temperature Management on Intestinal Flora and Its Metabolites in Patients With Cardiac Arrest Starting soon

Other trials for the same condition

Probiotic for Weight Management in Overweight and Obese Adults Starting soon

Influence of HDM1005 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin Starting soon

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes Active, not recruiting

A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity Recruiting

China Longitudinal Aging and Cognitive Impairment Study Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07690384 on ClinicalTrials.gov ↗ ← All trials in China